All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 28, 2023
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Heartseed raises ¥2B to continue trials of iPSC-derived cardiomyocytes for heart failure

May 26, 2023
By Tamra Sami
No Comments
Heartseed Inc. raised ¥2 billion (US$14.3 million) in a series D round to continue the phase I/II Lapis trial of its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes for heart failure. The lead asset, HS-001, is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from iPSCs that are designed to restore heart muscle and function in patients with advanced heart failure.
Read More
Map of Australia with pills, vials and syringe

Ausmedtech 2023: Should Australian med techs bother commercializing products at home?

May 24, 2023
By Tamra Sami
No Comments
With venture capital quite scarce, Australian med techs often question whether it makes sense to try to commercialize their products in their home market or whether they should partner to go offshore, but there are other options, said presenters at the Ausmedtech 2023 conference in Adelaide May 24.
Read More
Chris-Picton-ANDHealth1.jpg

Andhealth 2023: Lack of reimbursement for digital health technology could choke innovation

May 23, 2023
By Tamra Sami
No Comments
Although digital health technologies are being developed at breakneck speed, policies to reimburse these new technologies are lacking and are desperately needed if Australia is to be competitive in the digital health space, said speakers during the Andhealth Digital Health Summit in Adelaide on May 23.
Read More

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases

May 23, 2023
By Tamra Sami
No Comments
Rona Therapeutics Co. Ltd. and Keymed Biosciences Co. Ltd. formed a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis, also known as severe kidney diseases.
Read More
Cuvis-joint-image.jpg

BIO Korea 2023: South Korean government funds keep innovators afloat during VC deep freeze

May 19, 2023
By Tamra Sami
No Comments
The venture capital market in South Korea is frozen shut, said presenters during the recent BIO Korea 2023 conference in Seoul, but Korea’s Medical Device Development Fund will help support domestic R&D efforts to the tune of ₩987 billion (US$738 million) over five years.
Read More

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases

May 19, 2023
By Tamra Sami
No Comments
Rona Therapeutics Co. Ltd. and Keymed Biosciences Co. Ltd. formed a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis, also known as severe kidney diseases.
Read More
Cancer

Guided, less toxic chemo for high-risk childhood leukemia

May 18, 2023
By Tamra Sami
No Comments
Although advances in chemotherapy have dramatically improved outcomes for children with leukemia, patients with high-risk and aggressive cancers require intense drug regimens that push safety limits. Researchers have formulated an antibody guidance system in mice that could empower chemotherapy against childhood leukemias while minimizing drug toxicity.
Read More
Elderly man with clenched hands holding head

US FDA approves Rexulti as first drug for agitation in Alzheimer’s dementia

May 16, 2023
By Tamra Sami and Karen Carey
On its May 10 PDUFA date, the U.S. FDA approved serotonin-dopamine modulator Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. and H. Lundbeck A/S for agitation in Alzheimer’s dementia, marking the first approved treatment for the indication.
Read More

BIO Korea 2023: South Korea takes large strides in gene therapy, regenerative medicine

May 16, 2023
By Tamra Sami
No Comments
When it comes to CAR T therapies, South Korea is trailing behind the U.S. and China, but the South Korean government sees cell and gene therapies as a space where the country can draw international investors, speakers said during the Bio Korea 2023 conference in Seoul on May 10.
Read More

BIO Korea 2023: Regulatory obstacles stall decentralized clinical trials in Korea

May 16, 2023
By Tamra Sami
No Comments
Keeping patients at the center of clinical trials is how the global pharma industry views decentralized clinical trials, but bureaucratic red tape from multiple agencies is preventing companies from deploying decentralized trials in South Korea, speakers said during the BIO Korea 2023 conference in Seoul on May 11.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 26, 2023.
  • FDA approved icons and medical professional

    Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

    BioWorld
    Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...
  • Illustration of pancreas

    Gene therapy to reverse T2D shows proof of concept at ASGCT

    BioWorld
    The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...
  • PET imaging of RELN-COLBOS (H3447R) carrier brain showing limited aggregation of tau

    Reelin’ in druggable protective pathways with second Alzheimer’s ‘escapee’

    BioWorld
    Investigators have identified a second individual who remained cognitively normal into his late 60s despite having the PSEN1 E280A mutation, which causes a...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing